A template to quantify the location and density of CD3 + and CD8 + tumor-infiltrating lymphocytes in colon cancer by digital pathology on whole slides for an objective, standardized immune score assessment.

Autor: Lea D; Gastrointestinal Translational Research Unit, Molecular Laboratory, Hillevåg, Stavanger University Hospital, Stavanger, Norway.; Department of Clinical Medicine, University of Bergen, Bergen, Norway.; Department of Pathology, Stavanger University Hospital, Stavanger, Norway., Watson M; Gastrointestinal Translational Research Unit, Molecular Laboratory, Hillevåg, Stavanger University Hospital, Stavanger, Norway.; Department of Clinical Medicine, University of Bergen, Bergen, Norway.; Department of Gastrointestinal Surgery, Stavanger University Hospital, Stavanger, Norway., Skaland I; Department of Pathology, Stavanger University Hospital, Stavanger, Norway., Hagland HR; Gastrointestinal Translational Research Unit, Molecular Laboratory, Hillevåg, Stavanger University Hospital, Stavanger, Norway.; Department of Chemistry, Bioscience and Environmental Engineering, Faculty of Science and Technology, University of Stavanger, Stavanger, Norway., Lillesand M; Department of Pathology, Stavanger University Hospital, Stavanger, Norway., Gudlaugsson E; Department of Pathology, Stavanger University Hospital, Stavanger, Norway., Søreide K; Gastrointestinal Translational Research Unit, Molecular Laboratory, Hillevåg, Stavanger University Hospital, Stavanger, Norway. ksoreide@mac.com.; Department of Clinical Medicine, University of Bergen, Bergen, Norway. ksoreide@mac.com.; Department of Gastrointestinal Surgery, Stavanger University Hospital, Stavanger, Norway. ksoreide@mac.com.
Jazyk: angličtina
Zdroj: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2021 Jul; Vol. 70 (7), pp. 2049-2057. Date of Electronic Publication: 2021 Jan 13.
DOI: 10.1007/s00262-020-02834-y
Abstrakt: Background: In colon cancer, the location and density of tumor-infiltrating lymphocytes (TILs) can classify patients into low and high-risk groups for prognostication. While a commercially available 'Immunoscore ® ' exists, the incurred expenses and copyrights may prevent universal use. The aim of this study was to develop a robust and objective quantification method of TILs in colon cancer.
Methods: A consecutive, unselected series of specimens from patients with colon cancer were available for immunohistochemistry and assessment of TILs by automated digital pathology. CD3 + and CD8 + cells at the invasive margin and in tumor center were assessed on consecutive sections using automated digital pathology and image analysis software (Visiopharm ® ). An algorithm template for whole slide assessment, generated cell counts per square millimeters (cells/mm 2 ), from which the immune score was calculated using distribution volumes. Furthermore, immune score was compared with clinical and histopathological characteristics to confirm its relevance.
Results: Based on the quantified TILs numbers by digital image analyses, patients were classified into low (n = 83, 69.7%), intermediate (n = 14, 11.8%) and high (n = 22, 18.5%) immune score groups. High immune score was associated with stage I-II tumors (p = 0.017) and a higher prevalence of microsatellite instable (MSI) tumors (p = 0.030). MSI tumors had a significantly higher numbers of CD3 + TILs in the invasive margin and CD8 + TILs in both tumor center and invasive margin, compared to microsatellite stable (MSS) tumors.
Conclusion: A digital template to quantify an easy-to-use immune score corresponds with clinicopathological features and MSI in colon cancer.
Databáze: MEDLINE
Externí odkaz: